The human microbiome plays a critical role in our health, influencing everything from disease development to treatment responses.
Galderma deprioritizes study for IL-31 drug; UCB stops work in rare encephalitis
Plus, news about GlycoMimetics and Indivior: Galderma stops plans to develop nemolizumab in Phase 2: The Swiss dermatology company said it … Sign up to